Stock Update (NYSE:MRK): Merck expects to be denied approval for sugammadex injection again

[Reuters] – Merck & Co Inc said it expected to be denied U.S. approval for its sugammadex injection, after the U.S. Food and Drug Administration said it would conduct additional site inspections related . . . → Read More: Stock Update (NYSE:MRK): Merck expects to be denied approval for sugammadex injection again Similar Articles: Company Update: Merck & Co Inc (NYSE:MRK) – Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Present at the 35th Annual Cowen Health Care Conference Stock Update (NYSE:MRK): Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO® (tedizolid phosphate)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.